Lifecycle upsell Aquila positions itself as a full lifecycle publishing partner, suggesting opportunities to expand from regulatory submissions to ongoing lifecycle management, internal RegOps system development, and cost-optimized outsourcing for long-term clients.

Speed as differentiator With claims of most submissions completed within 24 hours and a focus on ‘First Pass’ approvals, there is a clear sales angle to target pharma and biotech teams needing rapid regulatory publishing to accelerate time-to-market and reduce cycle risks.

Lifecycle cost leverage The emphasis on lowest cost solutions and internalization of systems presents value in offering packaged services, blended sourcing models, and scalable pricing for sponsors seeking cost containment across multiple submissions and lifecycle activities.

Regulatory tech uplift Current tech stack including iCIMS, WordPress, Google Cloud, and SAS data considerations signals opportunities to upsell RegOps automation, data packaging, and eCTD publishing workflow enhancements integrated with sponsor systems.

Mid-market focus Company size and revenue suggest a strong fit for mid-sized biotech and pharma clients or sponsors with frequent regulatory submissions, presenting a scalable target market for repeat engagements and cross-sell into SPL, CTAs, and ClinicalTrials.gov submissions.